09-June-2026
Corporate News
 
J&J to buy cancer drug technology developer Firefly Bio for $1 billion
09-Jun-2026

Johnson & Johnson (JNJ.N), opens new tab said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks to expand its cancer drug pipeline. Firefly's Firelink platform uses antibodies to deliver a protein-degrading drug directly into cancer cells, an approach J&J says could help attack tumors while sparing more healthy tissue than existing treatments.

News Source:- https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-buy-firefly-bio-1-billion-2026-06-08/
 
 
 

Notes:
1. Copyright and ownership of all content from IMC and other IMC sites belongs to IMC except third-party resources
2. Copyright, intellectual property right, ownership or responsibility of error of other content belong to respective sources
3. Please do not reply to this mail

For suggestions and feedback click here.

Disclaimer:
IMC is not responsible for any kind of loss arising due to the information. You are receiving this newsletter because you have subscribed to this service. To unsubscribe click here.
Head Office : IMC Bldg., IMC Marg, Churchgate, Mumbai - 400 020 India  |   Tel : 91-22-22046633  |   Fax : 91-22-22048508 / 22838281
E-Mail : imc@imcnet.org  |   Website : www.imcnet.org